STA-5312

DRUG2 trials

Sponsors

Synta Pharmaceuticals Corp.

Conditions

Advanced or Metastatic Solid TumorsHematological MalignanciesLeukemiaLymphomaMetastatic or Unresectable Solid Tumors

Phase 1

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

CompletedNCT00088101

Synta Pharmaceuticals Corp.Hematological Malignancies, Leukemia, Lymphoma +1

Start: 2004-02-29End: 2004-12-31Target: 42Updated: 2008-12-04

A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors

CompletedNCT00276913

Synta Pharmaceuticals Corp.Advanced or Metastatic Solid Tumors

Start: 2004-06-30Target: 30Updated: 2014-02-03